Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.54 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.54 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.54 |
| ▸ | STS | P08842 | 4/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6611882 | 0.90 | HSD11B1 (0.45) | HSD11B1HSD17B1HSD17B2STSTGFBR1 | |
| SCHEMBL20899653 | 0.88 | HSD11B1 (0.56) | HSD11B1HSD17B1HSD17B2SLC40A1MAPK1 | |
| SCHEMBL6616008 | 0.88 | HSD11B1 (0.64) | HSD11B1HSD17B1HSD17B2SLC40A1 | |
| SCHEMBL6616875 | 0.87 | HSD11B1 (0.66) | HSD11B1HSD17B1HSD17B2SLC40A1 | |
| SCHEMBL6615038 | 0.86 | HSD11B1 (0.57) | HSD11B1HSD17B1HSD17B2SLC40A1MAPK1 | |
| SCHEMBL6611463 | 0.85 | HSD11B1 (0.55) | HSD11B1HSD17B1HSD17B2SLC40A1MAPK1 | |
| SCHEMBL6624322 | 0.85 | HSD11B1 (0.55) | HSD11B1HSD17B1HSD17B2SLC40A1 | |
| SCHEMBL6613085 | 0.84 | HSD11B1 (0.54) | HSD11B1HSD17B1HSD17B2STSTGFBR1 | |
| SCHEMBL3605403 | 0.83 | HSD11B1 (0.79) | HSD11B1HSD17B1HSD17B2STSPOLB | |
| SCHEMBL5831277 | 0.82 | HSD11B1 (0.58) | HSD11B1HSD17B1HSD17B2STSPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004112779-A1 | NEW USE VII | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| WO-2004112779-A1 | NEW USE VII | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.